Alvotech () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Prothena Corp. Plc

Blueprint Medicines Corp.

Krystal Biotech, Inc.

Axsome Therapeutics, Inc.

Intellia Therapeutics, Inc.

Denali Therapeutics, Inc.

CRISPR Therapeutics AG

Arrowhead Pharmaceuticals, Inc.

Alvotech

ImmunoGen, Inc.

Mirati Therapeutics, Inc.

Why is Alvotech ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -7.56
The company has been able to generate a Return on Capital Employed (avg) of 6.75% signifying low profitability per unit of total capital (equity and debt)

With a fall in Net Sales of -38.94%, the company declared Very Negative results in Jun 26

The company has declared negative results for the last 2 consecutive quarters
NET PROFIT(Q) At USD -66.82 MM has Fallen at -308.57%
RAW MATERIAL COST(Y) Grown by 11.95% (YoY)
INVENTORY TURNOVER RATIO(HY) Lowest at 1.02 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -24.94%, its profits have risen by 116.6% ; the PEG ratio of the company is 0.1

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Alvotech for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Alvotech

-24.94%

-0.73

81.38%

S&P 500

15.36%

1.17

13.11%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

256.02%

EBIT Growth (5y)

37.21%

EBIT to Interest (avg)

-7.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-3.54

Sales to Capital Employed (avg)

0.69

Tax Ratio

4.43%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

7.26%

ROCE (avg)

6.75%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-6.10

EV to EBIT

52.95

EV to EBITDA

28.36

EV to Capital Employed

2.37

EV to Sales

3.81

PEG Ratio

0.13

Dividend Yield

ROCE (Latest)

4.47%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -683.64 %

DEBTORS TURNOVER RATIO(HY)

Highest at 3.64 times

-29What is not working for the Company

NET PROFIT(Q)

At USD -66.82 MM has Fallen at -308.57%

RAW MATERIAL COST(Y)

Grown by 11.95% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.02 times

NET SALES(Q)

Lowest at USD 105.77 MM

OPERATING PROFIT(Q)

Lowest at USD -1.51 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -1.43 %

PRE-TAX PROFIT(Q)

Lowest at USD -66.76 MM

Here's what is working for Alvotech

Debt-Equity Ratio

Lowest at -683.64 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 3.64 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Alvotech

Net Sales

At USD 105.77 MM has Fallen at -38.94%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -66.76 MM has Fallen at -817.1%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -66.82 MM has Fallen at -308.57%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

Lowest at USD 105.77 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -1.51 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -1.43 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -66.76 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Inventory Turnover Ratio

Lowest at 1.02 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost

Grown by 11.95% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales